Gilteritinib For Patients With FLT3+ AML

Gilteritinib For Patients With FLT3+ AML

obr

1 year
106 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Edward Copelan, MD Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute Discusses Gilteritinib For Patients With FLT3+ AML At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com
Up Next Autoplay